-
Application of Distributional Cost-Effectiveness Analysis to the US Setting
Sep 21, 2023, 14:58 PM -
Innovative Uses of Technology to Advance Health Preference Research
Sep 21, 2023, 12:28 PM -
The Use of Real-World Evidence in HTA in Central and Eastern Europe
Sep 15, 2023, 11:46 AM -
Communicating High Value in Scientific Publications
Sep 12, 2023, 15:01 PM -
Driving Health Outcomes: Exploring Value-Based Procurement
Aug 24, 2023, 10:54 AM -
Health is Wealth
Jul 27, 2023, 13:25 PM -
Economic Evaluation of Digital Health Technologies
Jul 26, 2023, 11:16 AM -
Assessing Causal Treatment Effect for Sequenced Oncology Regimens
Jul 17, 2023, 09:58 AM -
FDA Patient-Focused Drug Development (PFDD) Guidance - Part 3
Jul 5, 2023, 09:26 AM -
Assessment of Digital Health Technologies in the Asia Pacific Region
Jun 9, 2023, 09:48 AM -
Challenges in Rare Disease Diagnostics: An Overview
Jun 5, 2023, 15:35 PM -
Clinical Trial Innovation: How Healthcare Technology is Evolving
Jun 1, 2023, 09:44 AM -
Introduction to Open-Source Modeling: R We There Yet?
Apr 23, 2023, 15:45 PM -
Health Equity in HEOR: Past, Present & Future Research Implications
Apr 5, 2023, 08:00 AM -
FDA Patient-Focused Drug Development (PFDD) Guidance - Part 2
Mar 8, 2023, 13:22 PM -
Improving Treatment Access and Outcomes by Integrating Social Determinants of Health Data With Real-World Evidence
Feb 23, 2023, 15:45 PM -
Preventing, Detecting, and Analyzing Data From Suspected Fraudulent Respondents in Online Surveys, with Examples From Health Preference Studies
Feb 17, 2023, 10:47 AM -
Digital Endpoint Adoption: the How, What and Why
Feb 10, 2023, 12:54 PM -
FDA Patient-Focused Drug Development (PFDD) Guidance - Part 1
Feb 7, 2023, 12:48 PM -
Achieving Fit for Purpose Data from Wearables for Age-Related Diseases
Jan 13, 2023, 15:25 PM